Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study | Zendy

Isabelle CédrinDurnerin | Zendy; D Grange-Dujardin | Zendy; A Laffy | Zendy; I Parneix | Zendy; Nathalie Massin | Zendy; Julie Galey | Zendy; Laëtitia Théron | Zendy; JeanPhilippe Wolf | Zendy; Cyrille Conord | Zendy; Patrice Clément | Zendy; S Jayot | Zendy; JeanNoël Hugues | Zendy

Open Access

Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study

Author(s) -

Isabelle CédrinDurnerin,

D Grange-Dujardin,

A Laffy,

I Parneix,

Nathalie Massin,

Julie Galey,

Laëtitia Théron,

JeanPhilippe Wolf,

Cyrille Conord,

Patrice Clément,

S Jayot,

JeanNoël Hugues

Publication year - 2004

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deh369

Subject(s) - antagonist , gonadotropin releasing hormone antagonist , follicular phase , medicine , hormone antagonist , randomized controlled trial , andrology , endocrinology , gynecology , gonadotropin releasing hormone , luteinizing hormone , hormone , receptor

When administered in the late follicular phase to prevent an LH surge, GnRH antagonists induce a sharp decrease in serum LH levels that may be detrimental for assisted reproductive technology cycle outcome. Therefore, a prospective study was designed to assess the effects of recombinant human (r)LH supplementation during GnRH antagonist (cetrorelix) administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research